Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
25 drugs in development
By Therapeutic Area
top 6
R&D Momentum
85/100
Pipeline Velocity
50/100
Trial Completion Rate
77/100
Pipeline Concentration
13/100
Pipeline Freshness
62/100
Strategic Signals
Activity
Last 14 days
Comparison of Methods in Post Operative Knee Arthroscopy Rehabilitation
A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine-gynx and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer
Mechanistic Investigation of Therapies for Down Syndrome Regression Disorder
Quadriceps Tendon Autograft, Tendon-Bone Versus All-Soft-Tissue for Anterior Cruciate Ligament Reconstruction: A Patient-Blinded Randomized Clinical Trial
The Intersection of Oncology Care and Worker Well-Being
Feasibility and Effectiveness of an Innovative Exercise Program to Reduce Fatigue in Rural Cancer Survivors
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure With Reduced Ejection Fraction: I-I-CAPTAIN-HF
Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients
Phase 1 Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients With Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)
Relationships Between Physical Activity and Different Measures of Fatigue in Cancer Survivors
Vibrotactile Stimulation for Parkinson's Disease
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)